Recent advances on nontuberculous mycobacteria diseases in Asia  by Hsueh, Po-Ren
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 4 ( 2 0 1 5 ) 4 0
.sc iencedi rect .comHO ST E D  BY Avai lab le at wwwScienceDirect
journal homepage: www.elsev ier .com/ locate / IJMYCORecent advances on nontuberculous mycobacteria
diseases in Asiahttp://dx.doi.org/10.1016/j.ijmyco.2014.11.012
2212-5531/ 2015 Published by Elsevier Ltd. on behalf of Asian-African Society for Mycobacteriology.Po-Ren Hsueh
Divisions of Clinical Microbiology and Infectious Diseases, Departments of Laboratory Medicine and Internal Medicine,
National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, TaiwanA R T I C L E I N F O
Article history:
Received 13 November 2014
Accepted 17 November 2014
Available online 24 December 2014
Keywords:
Nontuberculous mycobacteria
AsiaThe isolation rate of nontuberculous mycobacteria (NTM) species and the prevalence of
NTM-associated diseases are on the rise worldwide; however, the species distribution of
NTM isolates and the types of diseases caused by NTM species vary from region to region.
Treatment of a NTM disease is complicated, and there is no comprehensive guideline
regarding the in vitro susceptibility of each antimicrobial agent against NTM. Therefore,
appropriate anti-NTM treatment can only be recommended based on individual NTM spe-
cies and local surveillance studies of anti-NTM resistance. Previous studies on the in vitro
susceptibility of Mycobacterium avium complex (MAC) to clarithromycin in some Asian
countries have revealed a low rate of resistance to that antimicrobial agent. Thus, a clari-
thromycin-based anti-MAC regimen should be effective for MAC infections. However, clar-
ithromycin resistance due to the mutation of the 23S rRNA gene in MAC strains has been
detected in many countries. Therefore, physicians should avoid monotherapy with clari-
thromycin and consider the possibility of clarithromycin resistance in patients who do
not respond to clarithromycin-based regimens. Rifampicin is the critical component of suc-
cessful management of Mycobacterium kansasii diseases. Although most M. kansasii isolates
are susceptible to rifampicin in Western countries and in Japan, this agent may not work
well in Taiwan. Rapidly growing mycobacteria (RGM) is a prevalent NTM group worldwide,
particularly in Asia; however, each NTM species in this group may have its own distinct
antibiotic susceptibility pattern, and close monitoring of the antibiotic-resistance patterns
of RGM is necessary. Most important of all, the in vitro susceptibility may not represent the
in vivo activity until the confirmation of the clinical study. Therefore, further investigation
of the clinical effectiveness of the anti-NTM agents is warranted.
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